Some of the speculation about B seems a bit over the top to me. This will be a Phase 2b result, with a big phase 3 yet to go. A successful Phase 2b...parity in effectiveness/win in dose regimen and compliance/parity or better in side effects...means B is worth at as much as 800 million or 5 bucks a share fully diluted. I think the reality will be more like $3.50. Tedizolid and all of Trius was gobbled up by Cubist after Phase 3 success for around 800 million. B would perhaps be worth more than that after Phase 3, but not, imo, after this trial. Moreover, there is some doubt (40%?) about whether B will achieve this kind of trial result.
Success, and a year from now CTIX is at 5-7 bucks, not considering K, P, or other B possibilities. NOT BAD.
Market Data 
Markets 
AI
